Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics plc (NASDAQ: BCYC) is a clinical-stage pharmaceutical company developing Bicycle molecules, Bicycle Drug Conjugates (BDC) and Bicycle Radioconjugates (BRC) for oncology indications. News about BCYC often centers on progress across its clinical pipeline, strategic collaborations, and financial updates that shape the company’s development plans.
Investors and observers following BCYC news can expect regular updates on clinical trials such as the Duravelo-1 Phase 1 study, the Duravelo-2 Phase 2/3 pivotal trial in metastatic urothelial cancer, and the Duravelo-3 and Duravelo-4 Phase 1/2 studies in Nectin-4–amplified breast cancer and non-small cell lung cancer. The company also reports on data presentations at major scientific meetings, including imaging and clinical data for BRC molecules targeting EphA2 and MT1-MMP.
Company news also covers strategic partnerships, including long-term arrangements with the UK Nuclear Decommissioning Authority, the United Kingdom National Nuclear Laboratory, and SpectronRx to support an end-to-end 212Pb radiopharmaceutical supply chain. Additional announcements highlight Board of Directors changes, formation and expansion of the Research and Innovation Advisory Board, and inducement grants to new employees under the 2024 Inducement Plan.
On this BCYC news page, readers can track press releases on quarterly financial results, regulatory interactions related to zelenectide pevedotin’s potential approval pathway, and anticipated milestones such as dose selection decisions and data disclosures. For those researching Bicycle Therapeutics stock, this news feed provides a centralized view of the company’s operational, clinical, and corporate developments over time.
Bicycle Therapeutics plc (Nasdaq: BCYC) has launched an underwritten public offering of $125 million in American Depositary Shares (ADSs), with an option for underwriters to purchase an additional $18.75 million. The funds will support the advancement of Bicycle's product pipeline and general corporate purposes. The offering is subject to market conditions and may not be completed as planned. Major financial institutions managing the offering include Goldman Sachs, Morgan Stanley, and SVB Leerink.
Bicycle Therapeutics (NASDAQ: BCYC) reported promising interim results from its Phase I trials for BT5528 and BT8009 targeting advanced cancers. BT5528 showed 100% tumor reduction in urothelial patients and an 80% disease control rate in ovarian cancer patients. A recommended Phase II dose of 6.5-8.5mg/m² every other week was established. In the BT8009 trial, 36% of urothelial patients had partial responses. Both drugs were well tolerated with no dose-limiting toxicities noted. Expansion cohorts for BT5528 are expected to start in 2022.
Bicycle Therapeutics (NASDAQ: BCYC) has announced that interim Phase I results from its Phase I/II trial of BT5528, a second-generation Bicycle® Toxin Conjugate targeting EphA2, will be presented at the AACR-NCI-EORTC Virtual International Conference on October 7-10, 2021. The plenary oral presentation will be conducted by Dr. Meredith McKean from the Sarah Cannon Research Institute. The company will also host a conference call on October 7, 2021, at 3:00 p.m. ET to discuss these results and updates from the BT8009 program.
Bicycle Therapeutics plc (NASDAQ: BCYC) announced its participation in several investor conferences throughout September 2021. Key events include the Goldman Sachs Eleventh Annual Biotech Symposium on September 7, a pre-recorded presentation at H.C. Wainwright's Global Investment Conference on September 13, the Morgan Stanley Global Healthcare Conference on September 14, and the Cantor Virtual Global Healthcare Conference on September 27. Live webcasts of these events will be available on Bicycle's website, with archived replays accessible for 30 days.
Bicycle Therapeutics plc (NASDAQ: BCYC) reported second-quarter financial results for 2021, highlighting significant clinical progress and corporate updates. The company received $45 million from a licensing agreement with Ionis Pharmaceuticals for developing targeted oligonucleotide therapeutics and has strengthened its balance sheet with $14.4 million raised from its ATM offering. Cash reserves stood at $198.7 million as of June 30, expected to finance clinical milestones into 2024. However, the company reported a net loss of $17.9 million, or $(0.74) per share, an increase from a $12.1 million loss in Q2 2020.
Ionis Pharmaceuticals has entered an exclusive licensing agreement with Bicycle Therapeutics to enhance its LIgand Conjugated Antisense (LICA) medicines. The deal grants Ionis access to Bicycle's proprietary Bicycles, targeting transferrin receptor 1 to improve delivery of oligonucleotides. Ionis made a $45 million upfront payment, which includes a license fee and equity investment. This partnership aims to boost Ionis' drug discovery capabilities, potentially leading to better treatment options for patients.
Bicycle Therapeutics (NASDAQ: BCYC) has announced an exclusive licensing agreement with Ionis Pharmaceuticals for the use of its proprietary Bicycle® technology in delivering oligonucleotide therapeutics targeting the transferrin receptor (TfR1). Bicycle will receive $45 million upfront, including an $11 million equity investment, and is eligible for further milestone payments and royalties. This collaboration aims to leverage the selective delivery capabilities of Bicycles for precision medicines across various therapeutic areas, including skeletal and cardiac muscle diseases.
Bicycle Therapeutics (NASDAQ: BCYC) provided an update regarding its 2021 Annual General Meeting (AGM) scheduled for June 28, 2021. Due to ongoing COVID-19 restrictions in the UK, shareholders will not be allowed to attend the AGM in person. Instead, they are encouraged to vote by proxy and appoint the Chairman as their proxy. The company is conducting Phase I/II clinical trials for its drug candidates, including BT5528 and BT8009, targeting specific tumor antigens. The AGM will take place at Bicycle's headquarters in Cambridge, UK, at 1:00 p.m. London time.
Bicycle Therapeutics plc (NASDAQ: BCYC) announced its participation in three virtual investor conferences in June 2021. The events include:
- Jefferies Virtual Healthcare Conference on June 3 at 11:00 a.m. ET
- Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 8:00 a.m. ET
- JMP Securities Life Sciences Conference on June 17 at 12:00 p.m. ET
Investors can access live webcasts on the company’s website, with archives available for 30 days post-event. Bicycle focuses on developing its proprietary Bicycle® technology for treating underserved diseases.
Bicycle Therapeutics (NASDAQ: BCYC) announced its financial results for Q1 2021, reporting cash of $195.9 million, an increase from $136.0 million at the end of 2020. The company is advancing its Bicycle Toxin Conjugates and plans to enter the clinic with lead compound BT7480 later this year. Research & development expenses rose to $9.7 million with a net loss of $16.2 million for the quarter. Bicycle continues to strengthen its balance sheet through an ATM offering, raising $75 million since January 2021. The firm is optimistic about its clinical milestones through 2024.
FAQ
What is the current stock price of Bicycle Therapeutics (BCYC)?
What is the market cap of Bicycle Therapeutics (BCYC)?
